{"transactions":[{"id":711025,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T20:15:11.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":7500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001193125-26-300922","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526300922/ownership.xml","form_type":"4"}},{"id":855448,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-06T21:33:50.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":22500,"derivative":{"exercise_price":9.13,"expiration_date":"2036-03-03","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001193125-26-096692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526096692/ownership.xml","form_type":"4"}},{"id":1018413,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2025-10-15T11:55:27.000Z","date":"2025-10-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2881,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On October 9, 2025, pursuant to that certain Business Combination Agreement, dated July 13, 2025 (as amended by the Amendment Agreement, dated September 23, 2025, the \"Agreement\"), by and among the Issuer, XenoTherapeutics, Inc., Xeno Acquisition Corp. (\"Purchaser\") and XOMA Royalty Corporation, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) cash consideration of approximately US$0.12 per share and (ii) one contingent value right (\"CVR\") for each common share entitling its holder to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the transactions contemplated by the Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-099644","document":"tm2528208-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000110465925099644/tm2528208-1_4seq1.xml","form_type":"4"}},{"id":1273476,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-11T21:15:12.000Z","date":"2025-02-07","kind":"grant","planned":false,"acquired":true,"shares":650000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":650000,"derivative":{"exercise_price":0.782,"expiration_date":"2035-02-06","underlying":"Common Stock","underlying_shares":650000},"source":{"system":"sec-edgar","filing":"0000950170-25-017916","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017025017916/ownership.xml","form_type":"4"}},{"id":1465736,"issuer":{"id":74418,"kind":"organization","name":"Carisma Therapeutics Inc.","symbol":"CARM"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-01T19:19:29.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":38700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest over three years in equal monthly installments following July 1, 2024, subject to continued service to Carisma Therapeutics Inc. through the applicable vesting date."}],"balance_after":38700,"derivative":{"exercise_price":1.67,"expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":38700},"source":{"system":"sec-edgar","filing":"0001104659-24-076988","document":"tm2418517-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485003/000110465924076988/tm2418517-4_4seq1.xml","form_type":"4"}},{"id":1558410,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true}}],"security":"Options","published_at":"2024-03-28T12:40:22.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50000,"derivative":{"exercise_price":9.04,"exercise_date":"2025-03-25","expiration_date":"2034-03-25","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950172-24-000140","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000095017224000140/form4.xml","form_type":"4"}},{"id":1559215,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Options (right to buy)","published_at":"2024-03-27T20:20:09.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":700000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on March 25, 2025.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":700000,"derivative":{"exercise_price":0.79,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":700000},"source":{"system":"sec-edgar","filing":"0000950170-24-037213","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000095017024037213/ownership.xml","form_type":"4"}},{"id":1746791,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-11-08T20:31:37.000Z","date":"2023-11-07","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. These RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the Reporting Person's continued service to the issuer on each such vesting date. These RSUs have no expiration date."}],"balance_after":6500,"derivative":{"underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001694665-23-000175","document":"wk-form4_1699493485.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000175/wk-form4_1699493485.xml","form_type":"4"}},{"id":1746790,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-08T20:31:37.000Z","date":"2023-11-08","kind":"sale","planned":true,"acquired":false,"shares":1811,"price":0.33,"value":597.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.32 to $0.34, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":22259,"source":{"system":"sec-edgar","filing":"0001694665-23-000175","document":"wk-form4_1699493485.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000175/wk-form4_1699493485.xml","form_type":"4"}},{"id":1746789,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-08T20:31:37.000Z","date":"2023-11-07","kind":"exercise","planned":true,"acquired":true,"shares":6500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":24070,"source":{"system":"sec-edgar","filing":"0001694665-23-000175","document":"wk-form4_1699493485.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000175/wk-form4_1699493485.xml","form_type":"4"}},{"id":1749846,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-11-03T16:11:13.000Z","date":"2023-11-01","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in three (3) substantially equal installments on each of November 1, 2023, February 1, 2024 and May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. These RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in three (3) substantially equal installments on each of November 1, 2023, February 1, 2024 and May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. These RSUs have no expiration date."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001694665-23-000167","document":"wk-form4_1699042256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000167/wk-form4_1699042256.xml","form_type":"4"}},{"id":1749845,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-03T16:11:13.000Z","date":"2023-11-02","kind":"sale","planned":true,"acquired":false,"shares":3999,"price":0.33,"value":1319.67,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $0.31 to $0.33, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":17570,"source":{"system":"sec-edgar","filing":"0001694665-23-000167","document":"wk-form4_1699042256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000167/wk-form4_1699042256.xml","form_type":"4"}},{"id":1749844,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-03T16:11:13.000Z","date":"2023-11-01","kind":"exercise","planned":true,"acquired":true,"shares":12500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":21569,"source":{"system":"sec-edgar","filing":"0001694665-23-000167","document":"wk-form4_1699042256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000167/wk-form4_1699042256.xml","form_type":"4"}},{"id":1782094,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-09-13T20:55:07.000Z","date":"2023-09-11","kind":"grant","planned":false,"acquired":true,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in three (3) substantially equal installments on each of November 1, 2023, February 1, 2024 and May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. These RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in three (3) substantially equal installments on each of November 1, 2023, February 1, 2024 and May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date. These RSUs have no expiration date."}],"balance_after":37500,"derivative":{"underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0001694665-23-000155","document":"wk-form4_1694652898.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000155/wk-form4_1694652898.xml","form_type":"4"}},{"id":1812032,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-09T20:42:02.000Z","date":"2023-08-07","kind":"exercise","planned":true,"acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date."}],"balance_after":13000,"derivative":{"underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001694665-23-000133","document":"wk-form4_1691628110.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000133/wk-form4_1691628110.xml","form_type":"4"}},{"id":1812031,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-09T20:42:02.000Z","date":"2023-08-08","kind":"sale","planned":true,"acquired":false,"shares":2004,"price":9.51,"value":19058.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $9.08 to $9.55, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":9069,"source":{"system":"sec-edgar","filing":"0001694665-23-000133","document":"wk-form4_1691628110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000133/wk-form4_1691628110.xml","form_type":"4"}},{"id":1812030,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-09T20:42:02.000Z","date":"2023-08-07","kind":"exercise","planned":true,"acquired":true,"shares":6500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":11073,"source":{"system":"sec-edgar","filing":"0001694665-23-000133","document":"wk-form4_1691628110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000133/wk-form4_1691628110.xml","form_type":"4"}},{"id":1898185,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-10T21:31:35.000Z","date":"2023-05-08","kind":"sale","planned":true,"acquired":false,"shares":38531,"price":0.1255,"value":4835.6405,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction entered into by the Reporting Person, solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is an average price. These shares were sold in multiple transactions at prices within the range of $0.12 to $0.13, inclusive. The reporting person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":91469,"source":{"system":"sec-edgar","filing":"0001694665-23-000052","document":"wf-form4_168376868122281.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000052/wf-form4_168376868122281.xml","form_type":"4"}},{"id":1899531,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-05-09T16:09:37.000Z","date":"2023-05-07","kind":"exercise","planned":false,"acquired":false,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date. These RSUs have no expiration date."}],"balance_after":390000,"derivative":{"underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001694665-23-000044","document":"wf-form4_168366296133059.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000044/wf-form4_168366296133059.xml","form_type":"4"}},{"id":1899530,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-09T16:09:37.000Z","date":"2023-05-07","kind":"exercise","planned":false,"acquired":true,"shares":130000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Issuer common stock."}],"balance_after":130000,"source":{"system":"sec-edgar","filing":"0001694665-23-000044","document":"wf-form4_168366296133059.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000044/wf-form4_168366296133059.xml","form_type":"4"}},{"id":2024804,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-02-09T16:25:19.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":520000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Restricted Stock Units vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Restricted Stock Units vest in four (4) substantially equal quarterly installments following the February 07, 2023 grant date, such that all of the Restricted Stock Units will become vested on the first anniversary of the grant date, subject to the reporting person's continued service to the issuer on each such vesting date."}],"balance_after":520000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":520000},"source":{"system":"sec-edgar","filing":"0001694665-23-000009","document":"wf-form4_167597789299363.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466523000009/wf-form4_167597789299363.xml","form_type":"4"}},{"id":2084718,"issuer":{"id":8336,"kind":"organization","name":"GRI Bio, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-12-15T21:26:39.000Z","date":"2022-12-13","kind":"other","acquired":false,"shares":28517,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Cancellation of unvested restricted stock units granted on July 1, 2022."}],"balance_after":9506,"source":{"system":"sec-edgar","filing":"0001824293-22-000082","document":"wf-form4_167113958127044.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000082/wf-form4_167113958127044.xml","form_type":"4"}},{"id":2128447,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-11-01T11:08:38.000Z","date":"2022-06-29","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the options vest after 12 months from the date of grant."}],"balance_after":22500,"derivative":{"exercise_price":3.6,"expiration_date":"2032-06-29","underlying":"Common Shares","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-22-054973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919122054973/doc4.xml","form_type":"4"}},{"id":2168999,"issuer":{"id":108468,"kind":"organization","name":"Evelo Biosciences, Inc.","symbol":"EVLO"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-01T16:52:50.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the underlying shares will vest on the first anniversary of the reporting person's employment commencement date (i.e., September 1, 2023), and the remaining 75% of the underlying shares will vest in 36 substantially equal monthly installments thereafter"}],"balance_after":440000,"derivative":{"exercise_price":2.29,"expiration_date":"2032-09-01","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001694665-22-000130","document":"wf-form4_166206555353252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1694665/000169466522000130/wf-form4_166206555353252.xml","form_type":"4"}},{"id":2211171,"issuer":{"id":8336,"kind":"organization","name":"GRI Bio, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-06T18:03:57.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":38023,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs vest in four (4) equal quarterly installments such that the RSU will be fully vested on the first (1st) anniversary of the date of grant, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of Vallon Pharmaceuticals, Inc."}],"balance_after":38023,"source":{"system":"sec-edgar","filing":"0001824293-22-000061","document":"wf-form4_165713062186980.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000061/wf-form4_165713062186980.xml","form_type":"4"}},{"id":2235227,"issuer":{"id":8336,"kind":"organization","name":"GRI Bio, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T17:31:44.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in four equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant."}],"balance_after":7500,"derivative":{"exercise_price":0.51,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001824293-22-000054","document":"wf-form4_165488229138396.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429322000054/wf-form4_165488229138396.xml","form_type":"4"}},{"id":2319637,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-23T16:56:30.000Z","date":"2022-03-21","kind":"other","acquired":true,"shares":52101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents ADSs received by the Reporting Person, for no consideration, pursuant to contingent value rights granted to the Reporting Person in January 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents ADSs received by the Reporting Person, for no consideration, pursuant to contingent value rights granted to the Reporting Person in January 2021."}],"balance_after":53101,"source":{"system":"sec-edgar","filing":"0000899243-22-011946","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826323/000089924322011946/doc4.xml","form_type":"4"}},{"id":2412682,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Share Option (right to buy)","published_at":"2022-02-03T18:30:38.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option shall vest and become exercisable in substantially equal monthly installments with the first installment vesting on March 1, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":67500,"derivative":{"exercise_price":9.53,"expiration_date":"2032-02-01","underlying":"Ordinary Shares","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0000899243-22-004686","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826323/000089924322004686/doc4.xml","form_type":"4"}},{"id":2680274,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Ordinary Shares","published_at":"2021-06-04T17:00:28.000Z","date":"2021-06-02","kind":"purchase","acquired":true,"shares":1000,"price":20,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0000899243-21-022065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826323/000089924321022065/doc4.xml","form_type":"4"}},{"id":2688391,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Share Option (right to buy)","published_at":"2021-06-01T20:47:46.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to such option shall vest and become exercisable on February 1, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F5","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":137500,"derivative":{"exercise_price":20,"expiration_date":"2031-05-27","underlying":"Ordinary Shares","underlying_shares":137500},"source":{"system":"sec-edgar","filing":"0000899243-21-021435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1826323/000089924321021435/doc4.xml","form_type":"4"}},{"id":2688390,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Share Option (right to buy)","published_at":"2021-06-01T20:47:46.000Z","date":"2021-02-19","kind":"grant","acquired":true,"shares":208474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to such option shall vest and become exercisable on February 19, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F5","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":208474,"derivative":{"exercise_price":5.84,"expiration_date":"2031-02-19","underlying":"Ordinary Shares","underlying_shares":208474},"source":{"system":"sec-edgar","filing":"0000899243-21-021435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1826323/000089924321021435/doc4.xml","form_type":"4"}},{"id":2688389,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Share Option (right to buy)","published_at":"2021-06-01T20:47:46.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":9487,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to such option are vested as of January 29, 2021.  The remaining 75% of the shares subject to such option shall vest and become exercisable monthly beginning on February 1, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F5","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":9487,"derivative":{"exercise_price":4.87,"expiration_date":"2030-12-30","underlying":"Ordinary Shares","underlying_shares":9487},"source":{"system":"sec-edgar","filing":"0000899243-21-021435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1826323/000089924321021435/doc4.xml","form_type":"4"}},{"id":2688388,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Accounting Officer"}}],"security":"Share Option (right to buy)","published_at":"2021-06-01T20:47:46.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":58956,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This transaction occurred prior to the effectiveness of the Issuer's registration under Section 12 of the Securities Exchange Act of 1934 and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3."},{"field":"shares","element":"transactionShares","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"56.25% of the shares subject to such option are vested as of January 29, 2021. The remaining 43.75% of the shares subject to such option shall vest and become exercisable monthly beginning on February 1, 2021."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F4","text":"Represents A Ordinary Shares that will be redesignated as Ordinary Shares immediately prior to the closing of the initial public offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F5","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On May 20, 2021, the Issuer effected a share capital reorganization, which had the effect of a one for two reverse share split of the Issuer's share capital (\"Stock Split\"). This amount has been adjusted to give effect to the Stock Split."}],"balance_after":58956,"derivative":{"exercise_price":4.11,"expiration_date":"2030-09-30","underlying":"Ordinary Shares","underlying_shares":58956},"source":{"system":"sec-edgar","filing":"0000899243-21-021435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826323/000089924321021435/doc4.xml","form_type":"4"}},{"id":2862064,"issuer":{"id":8336,"kind":"organization","name":"GRI Bio, Inc."},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-12T23:01:17.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 24 equal monthly installments such that the stock option shall be fully vested as of the second anniversary of the consummation of the initial public offering of the company's common stock."}],"balance_after":15000,"derivative":{"exercise_price":8,"expiration_date":"2031-02-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-022187","document":"tm214979d7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1824293/000110465921022187/tm214979d7_4seq1.xml","form_type":"4"}},{"id":2895172,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-26T19:03:21.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting terms have been amended such that 100% of the options vest after 12 months from the date of grant."}],"balance_after":16500,"derivative":{"exercise_price":7,"expiration_date":"2030-12-11","underlying":"Common Shares","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-21-005515","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919121005515/doc4a.xml","form_type":"4/A","original_submission_date":"2021-01-11"}},{"id":2910989,"issuer":{"id":15763,"kind":"organization","name":"ESSA Pharma Inc.","symbol":"EPIX"},"owners":[{"id":30936,"kind":"person","name":"Thorell Marella","position":1,"cik":"0001826323","reported_name":"Thorell Marella","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-11T16:46:27.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter."}],"balance_after":16500,"derivative":{"exercise_price":7,"expiration_date":"2030-12-11","underlying":"Common Shares","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-21-002954","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1633932/000120919121002954/doc4.xml","form_type":"4"}}]}